Quris.AI
Quris.AI is transforming drug safety prediction by uniquely combining advanced AI capabilities with cutting edge 3D organ models, enabling predictions with unprecedented accuracy and scalability. our platform has been extensively validated by leading Pharma companies, including a long term collaboration with Merck GmbH. By predicting safety in human relevant 3D models, our platform significantly increases the likelihood of clinical success and reduces significantly the need for animal testing.
TheWell Bioscience
TheWell Bioscience provides xeno-free, 3D cell culture solutions, empowering research in organoids, regenerative medicine, and drug discovery.
InSphero
InSphero is the pioneer of industrial-grade, 3D-microtissue-based assay solutions and scaffold-free 3D organ-on-a-chip technology. The company specializes in liver toxicology, metabolic diseases (e.g., T1 & T2 diabetes and NAFLD & NASH liver disease), and immuno oncology.
Hesperos Inc.
Hesperos is accelerating drug discovery by providing safety and efficacy testing services using its Human-on-a-Chip, microphysiological system. This breakthrough technology enables unprecedented preclinical insight bringing better therapies to patients faster without the need for animal testing.
TissUse
TissUse is a Berlin, Germany-based, biotechnology company who has developed a unique HUMIMIC Multi-Organ-Chip platform for advanced toxicity testing and cutting-edge disease modelling.
MIMETAS
Mimetas develops high-throughput healthy and diseased organ-on-a-chip models in the OrganoPlate®, a screening-compatible microfluidics platform that supports the recreation of native tissue structures, and their interaction with compounds, signaling factors, disease triggers, and co-cultured cell types.